Frontiers in Oncology最新文献

{"title":"The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC.","authors":"Yifan Wang, Jianying Zhou, Simin Peng, Zhao Cui, Weiqi Wang, Wenqin Zeng, Tingting Qiu, Zhentian Liu","doi":"10.3389/fonc.2025.1533556","DOIUrl":"10.3389/fonc.2025.1533556","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to investigate the specific effects of glucocorticoids (GC) on the efficacy of immune checkpoint inhibitors (ICIs), and whether this effect is influenced by the timing and dosage of GC administration. Changes in the neutrophil percentage and the helper/suppressor T lymphocyte ratio [NEUT %/(CD4+/CD8+)] during GC administration were monitored.</p><p><strong>Methods: </strong>The clinical results of 130 patients with advanced non-small cell lung cancer (NSCLC) treated with ICIs were analyzed and compared with those of patients who did not use GC. Cox proportional hazards regression model and Logistic regression analysis were used to analyze the factors affecting ORR and PFS, and t test was used to analyze the changes of NEUT %/(CD4 +/CD8 +) during GC use.</p><p><strong>Results: </strong>Multivariate Logistic analysis showed that GC use was associated with a higher ORR in 130 patients treated with ICIs [HR = 3.07,95% CI (1.31-7.21), P = 0.010]. Univariate Cox analysis showed that GC use was not significantly correlated with PFS [HR = 0.926,95% CI (0.603-1.420), P = 0.710]. Patients who used GC during the baseline period of ICIs treatment had a higher ORR than those who used GC at the early stage of ICIs treatment (65.4% vs 30.8%, p = 0.024). Multivariate Cox analysis showed that GC use had longer PFS [HR = 0.37,95% CI (0.17-0.78), p = 0.009]. The timing of GC use was different, and there was a difference in NEUT %/(CD4 +/CD8 +) levels before and after treatment. There was no significant difference in ORR and PFS between GC duration and dose.</p><p><strong>Conclusion: </strong>The use of GC helps to enhance the efficacy of immunotherapy. In particular, GC use during the baseline period leads to higher ORR and PFS, regardless of the dose or duration of GC use. The levels of NEUT %/(CD4+/CD8+) varied depending on the timing of GC administration.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1533556"},"PeriodicalIF":3.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143363826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between dietary antioxidants, serum albumin/globulin ratio and quality of life in esophageal squamous cell carcinoma patients: a 7-year follow-up study.","authors":"Juwei Zhang, Jinsong Zhou, Siting Chen, Yue Huang, Zheng Lin, Yuan Deng, Minglian Qiu, Zhisheng Xiang, Zhijian Hu","doi":"10.3389/fonc.2025.1428214","DOIUrl":"10.3389/fonc.2025.1428214","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the association between dietary antioxidant index (DAI) combined with serum albumin-to-globulin ratio (AGR) and postoperative Health-related quality of life (HRQOL) in patients with esophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>All patients were newly diagnosed with ESCC and underwent radical esophagectomy. Dietary data and routine blood tests were collected preoperatively to compute DAI and AGR. HRQOL was assessed over 7 years post-surgery via telephone follow-up and analyzed longitudinally using a time to deterioration (TTD) model. The deterioration times were compared using the log-rank test, and the association of the combined DAI and AGR index with postoperative quality of life in ESCC patients was examined through Cox regression models.</p><p><strong>Results: </strong>A total of 238 ESCC patients were included in the study. The results indicate that compared to the low DAI-AGR group, the high DAI-AGR group had a lower rate of deterioration events, and the time to deterioration in emotional functioning (p=0.014), dysphagia (p=0.042), and speech problems (p=0.023) were significantly delayed. Cox proportional hazard model revealed that preoperative high DAI-AGR was associated with improvement in emotional functioning (HR=0.575, 95% CI: 0.368-0.898) and speech problems (HR=0.525, 95% CI: 0.298-0.925) in ESCC patients postoperatively, which remained significant even after adjusting for covariates. The stratified analysis revealed that this improvement was associated with demographic and clinical characteristics.</p><p><strong>Conclusions: </strong>Our findings suggest that high preoperative DAI-AGR is linked to enhanced postoperative HRQOL in ESCC patients, offering crucial insights for patients, practitioners, and researchers.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1428214"},"PeriodicalIF":3.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic role of prognostic nutritional index in patients with bladder cancer: a systematic review and meta-analysis.","authors":"Jing Sun, Zhenzhen Li, Xiaming Zhu","doi":"10.3389/fonc.2024.1486389","DOIUrl":"10.3389/fonc.2024.1486389","url":null,"abstract":"<p><strong>Aims: </strong>An increasing number of studies have explored the prognostic significance of the prognostic nutritional index (PNI) in bladder cancer patients, but the results are inconsistent. This study systematically investigates the prognostic value of baseline PNI in patients with bladder cancer through a meta-analytic approach.</p><p><strong>Methods: </strong>The databases of PubMed, EmBase, and the Cochrane library were systematically searched for eligible studies from inception until April 2024. The prognostic outcomes including overall survival (OS) and recurrence-free survival (RFS). The summary outcomes were calculated using the random-effects model, and the exploratory analyses were performed by sensitivity and subgroup analyses.</p><p><strong>Results: </strong>Twelve retrospective studies involved 2,951 patients with bladder cancer were selected in final analysis. The summary results found low PNI were associated with poor OS (HR: 1.80; 95%CI: 1.54-2.10; <i>P</i><0.001) and RFS (HR: 1.53; 95%CI: 1.15-2.04; <i>P</i>=0.003). The association between low PNI and shorter OS was statistically significant in all subgroups. Additionally, the association between low PNI and RFS was also significant in most subgroups.</p><p><strong>Conclusions: </strong>This study found a significant association between low PNI and poor prognosis in bladder cancer patients. Further large-scale prospective study should be performed to verify this association, and assess the nutrition interventions for patients with bladder cancer.</p><p><strong>Systematic review registration: </strong>https://inplasy.com/inplasy-2024-8-0020/, identifier INPLASY202480020.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1486389"},"PeriodicalIF":3.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798790/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary enteric adenocarcinoma with progression disease after second - line therapy: a case report.","authors":"Ya Guo, Bin Zhang, Heng Zhang, Yunbin Gao, Haibo Zhao, Pei Jiang, Qing-Qing Yu","doi":"10.3389/fonc.2025.1509026","DOIUrl":"10.3389/fonc.2025.1509026","url":null,"abstract":"<p><p>Pulmonary enteric adenocarcinoma (PEAC, also known as Enteric-type adenocarcinoma of the lung, lung - ETAC) is a rare subtype of non-small cell lung cancer (NSCLC) that has the same morphological and immunohistochemical characteristics as colorectal adenocarcinoma and requires gastroenteroscopy to rule out lesions of enteric origin. As a rare solid tumor in lung cancer, PEAC has unique clinical outcome, imaging, pathological and molecular characteristics, and poor prognosis. However, the molecular characteristics and therapeutic biomarkers of PEAC are unclear, and its treatment remains challenging. In this case, we describe a 61-year-old man diagnosed with advanced primary PEAC with KRAS mutation. In the case of unknown PD-L1 expression status, first-line treatment was given to lung adenocarcinoma regimen (immunotherapy combined with chemotherapy), progression occurred after 2 cycles, and progression-free survival (PFS) was 1.5 months. Then the second-line XELOX regimen (oxaliplatin combined with capecitabine) was adjusted. The lesions were significantly reduced after 2 and 4 cycles, and the disease progressed again after 6 cycles, with a PFS of 4.5 months. Anlotinib targeted drugs were selected for third-line treatment, but considering the overall poor condition of the patient, the patient himself refused further treatment. Finally, after discharge, the patient went to the local hospital for nutritional support and symptomatic treatment. The results suggest that standard first-line therapies (immunotherapy plus chemotherapy) and colorectal cancer regimens may have a relatively limited impact on survival in KRAS-driver positive advanced PEAC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1509026"},"PeriodicalIF":3.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proof of concept of fully automated adaptive workflow for head and neck radiotherapy treatments with a conventional linear accelerator.","authors":"Gaia Muti, Marco M J Felisi, Angelo F Monti, Chiara Carsana, Roberto Pellegrini, Edoardo Salmeri, Mauro Palazzi, Paola E Colombo","doi":"10.3389/fonc.2025.1382537","DOIUrl":"10.3389/fonc.2025.1382537","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study is to evaluate the performance of an automatic workflow for head-and-neck (H&N) radiotherapy using a multi-atlas based auto-contouring software and an a-priori multicriteria plan optimization algorithm and implement an adaptive online approach with CBCT images. Two different modalities are investigated, the fluence-to-position (FTP) and the adapt-to-shape (ATS) approach.</p><p><strong>Materials and methods: </strong>Nine patients are used for the multi-atlas database. The organs at risk (OARs) of the H&N district and five additional structures (air, fat, tissue, bone and patient's exterior) subsequently used for the creation of the synthetic CT are auto-contoured with the Elekta ADMIRE^® software. The mCycle algorithm is used for the a-priori multicriteria plan calculation. A total of twenty H&N patients are selected for this step. The automatic plans are compared to manual VMAT plans by assessing differences in planning time, dose delivered to targets and OARs, and calculating the plan quality indexes (PQIs). Two patients are chosen for the retrospective CBCT adaptive online feasibility analysis. To assess the differences for the two adaptive modalities, the clinical goals for targets and OARs and the number of passed constraints are explored. An analysis of the timing for the different steps is carried out to assess its clinical applicability.</p><p><strong>Result: </strong>The dice of the five HU layer structures range between 0.66 and 0.99. The mCycle auto-planning significantly reduces planning time, from 2 hours to 10 minutes. The radiotherapist deems all plans clinically acceptable, and in the majority of cases the automatic plan is the preference choice. The automatic plans enhance OARs sparing and preserve a good target coverage, this is also confirmed by the PQIs result. Comparing FTP and ATS modes in adaptive radiotherapy, ATS exhibits superior outcomes, mostly in the target coverage. In the FTP techniques target coverage is inadequate and statistically different from the accepted values. In the ATS the results align with the initial approved values. Using the ATS mode the planning time takes around 14 minutes and approximately 20 minutes for the entire treatment.</p><p><strong>Conclusion: </strong>This study contributes to the advancement of automatic and adaptive radiotherapy, demonstrating the potential of an automated workflow in H&N treatments.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1382537"},"PeriodicalIF":3.5,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report.","authors":"Yang Zhang, Ke-Jie Li, Can Wang, Chang-Lin Zou, Meng Su","doi":"10.3389/fonc.2024.1503262","DOIUrl":"10.3389/fonc.2024.1503262","url":null,"abstract":"<p><p>Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. In this case report, we provide evidence of a novel ALK fusion, XPO1-ALK (intergenic), identified by next-generation DNA sequencing in a patient with advanced lung cancer. After 5 months of brigatinib targeted therapy, the patient clearly experienced tumor disintegration, and this treatment resulted in partial remission. To date, this patient has experienced 5 months of progression-free survival after brigatinib treatment. In addition to reporting the identification of a novel ALK fusion, XPO1-ALK (intergenic), and the sensitivity and safety of brigatinib treatment for lung cancer, this study increased the list of known ALK fusion partners in ALK-positive NSCLC. This case report has a significant clinical reference.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1503262"},"PeriodicalIF":3.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram prediction of overall survival in breast cancer patients post-surgery: integrating SEER database and multi-center evidence from China.","authors":"Yufen Zheng, Yuan Yuan, Minya Jin, Chunlong Wu","doi":"10.3389/fonc.2024.1470515","DOIUrl":"10.3389/fonc.2024.1470515","url":null,"abstract":"<p><strong>Purpose: </strong>Overall survival (OS) in postoperative breast cancer patients is influenced by various clinicopathological features. Current prognostic methods, such as the 7th edition of AJCC staging, have limitations. This study aims to construct and validate a comprehensive nomogram integrating multiple clinicopathological features to predict OS more accurately in breast cancer patients.</p><p><strong>Methods: </strong>We identified 60,445 .female patients who underwent breast cancer surgery between January 1, 2011, and December 31, 2015, from the Surveillance, Epidemiology, and End Results (SEER) database, randomly divided into training and internal validation cohorts. Additionally, data from 332 breast cancer surgery patients from four hospitals in Taizhou, Zhejiang Province, were included as an external validation cohort. Kaplan-Meier analysis assessed the impact of clinicopathological features on OS, and multivariable Cox regression identified independent prognostic factors. A nomogram based on these factors was constructed to predict 1-, 3-, and 5-year OS. Model predictive performance was evaluated using C-index, AUC, calibration curves, and decision curves during internal and external validation.</p><p><strong>Results: </strong>Multivariable Cox regression analysis identified age, pathological grade, AJCC stage, ER status, PR status, and HER2 status as independent prognostic factors used in the nomogram construction. The nomogram achieved a C-index of 0.724 (95% CI, 0.716-0.732) in the training cohorts, 0.717 (95% CI, 0.705-0.729) in the internal validation cohorts, and 0.793 (95% CI, 0.724-0.862) in the external validation cohorts, indicating strong discriminative ability. Calibration curves demonstrated good agreement between predicted and observed outcomes in all validation cohorts. Decision curve analysis showed that the nomogram provided maximum net benefit across all validation cohorts.</p><p><strong>Conclusion: </strong>The nomogram developed in this study integrates multiple clinicopathological features and provides a convenient and accurate tool for predicting individualized OS in breast cancer patients. This tool can optimize treatment strategies and improve patient prognosis.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1470515"},"PeriodicalIF":3.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion.","authors":"Carmine Pinto, Sara Lonardi, Evaristo Maiello, Erika Martinelli, Michele Prisciandaro, Lisa Salvatore, Andrea Sartore-Bianchi, Mario Scartozzi, Giuseppe Aprile, Chiara Cremolini, Alberto Sobrero","doi":"10.3389/fonc.2024.1502185","DOIUrl":"10.3389/fonc.2024.1502185","url":null,"abstract":"<p><p>The prolongation of survival along with the preservation of quality of life, possibly avoiding harmful cumulative toxicities, is the primary therapeutic aim for patients with metastatic colorectal cancer (mCRC) in the third-line setting. Several therapeutic options are now available, although some differences across countries in drug approval and the optimal therapeutic sequencing associated with each peculiar patient subgroup represent a clinical challenge for oncologists. Among various options, the SUNLIGHT trial showed how the combination of trifluridine/tipiracil (FTD/TPI) with bevacizumab is effective with an easily manageable toxicity profile compared to FTD/TPI alone. Of note, the efficacy is confirmed independently from KRAS mutational status and also for patients who had breaks in anti-vascular endothelial growth factor (anti-VEGF) therapy. Herein, we describe the current state of the art in the landscape of treatments after the second progression in mCRC. Based on a critical review of the literature aimed to guide clinicians in their daily decision-making, we point out that the combination of FTD/TPI with bevacizumab produces a clinical benefit in unselected mCRC patients. Therefore, the FTD/TPI plus bevacizumab regimen can represent a new standard of care for the treatment of patients with refractory mCRC who have progressed after two lines of therapy.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1502185"},"PeriodicalIF":3.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural killer cell engagers for cancer immunotherapy.","authors":"Shahryar Khoshtinat Nikkhoi, Geng Li, Arash Hatefi","doi":"10.3389/fonc.2024.1483884","DOIUrl":"10.3389/fonc.2024.1483884","url":null,"abstract":"<p><p>This review article explores the rapidly evolving field of bi-, tri-, and multi-specific NK cell engagers (NKCEs), highlighting their potential as a cutting-edge approach in cancer immunotherapy. NKCEs offer a significant advancement over conventional monoclonal antibodies (mAbs) by enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC). They achieve this by stably and selectively binding to both NK cell activating receptors and tumor-associated antigens (TAAs). Unlike traditional mAbs, which depend on the relatively transient interaction between their Fc region and CD16a, NKCEs establish more robust connections with a range of activating receptors (e.g., CD16a, NKG2D, NKp30, NKp46, NKG2C) and inhibitory receptors (e.g., Siglec-7) on NK cells, thereby increasing cancer cell killing efficacy and specificity. This review article critically examines the strategies for engineering bi-, tri-, and multi-specific NKCEs for cancer immunotherapy, providing an in-depth analysis of the latest advancements in NKCE platform technologies currently under development by pharmaceutical and biotech companies and discussing the preclinical and clinical progress of these products. While NKCEs show great promise, the review underscores the need for continued research to optimize their therapeutic efficacy and to overcome obstacles related to NK cell functionality in cancer patients. Ultimately, this article presents an overview of the current landscape and future prospects of NKCE-based cancer immunotherapy, emphasizing its potential to revolutionize cancer treatment.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1483884"},"PeriodicalIF":3.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models.","authors":"Andrea Mancini, Alessandro Colapietro, Loredana Cristiano, Alessandra Rossetti, Vincenzo Mattei, Giovanni Luca Gravina, Héctor Perez-Montoyo, Marc Yeste-Velasco, Jose Alfon, Carles Domenech, Claudio Festuccia","doi":"10.3389/fonc.2025.1538834","DOIUrl":"https://doi.org/10.3389/fonc.2025.1538834","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fonc.2022.943064.].</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1538834"},"PeriodicalIF":3.5,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}